Survodutide

Survodutide (BI 456906) is a long-acting dual agonist of GLP-1 and glucagon receptors developed by Boehringer Ingelheim. Based on an oxyntomodulin analog framework, survodutide is acylated with a C18 fatty acid for albumin binding and extended half-life suitable for once-weekly dosing. Like mazdutide, survodutide exploits the complementary mechanisms of GLP-1R activation (appetite reduction, insulin potentiation) and GCGR activation (hepatic fatty acid oxidation, energy expenditure). Survodutide has been investigated in Phase 2 clinical trials for both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The glucagon receptor component is of particular interest in MASH research because GCGR activation promotes hepatic lipid oxidation and may reduce liver fat content. Survodutide represents Boehringer Ingelheim’s entry into the incretin combination space alongside Novo Nordisk’s CagriSema and Lilly’s tirzepatide/retatrutide programs.

Survodutide has been investigated for its dual agonist activity at GLP-1 and glucagon receptors. GLP-1R activation in pancreatic beta cells potentiates glucose-dependent insulin secretion and in the CNS promotes satiety through POMC neuron activation and NPY/AgRP inhibition. GCGR activation in hepatocytes stimulates fatty acid oxidation through CPT-1 upregulation and increases energy expenditure via thermogenic mechanisms. Researchers observed that the GCGR component of survodutide is particularly relevant for liver fat reduction — glucagon signaling increases hepatic lipid oxidation and ketogenesis while reducing de novo lipogenesis. In MASH clinical trials, this hepatic mechanism is the primary rationale for dual agonism over pure GLP-1R agonism. Studies suggest that the net metabolic effect balances glucagon’s hyperglycemic potential with GLP-1’s glucose-lowering activity. The C18 fatty acid acylation enables albumin binding and once-weekly pharmacokinetics.

Phase 2 Obesity Data

Blüher et al. (2024) investigated survodutide in a Phase 2 trial in adults with overweight or obesity. Researchers observed dose-dependent body weight reductions with the highest dose group showing significant changes at 46 weeks [1].

MASH/NASH Research

Sanyal et al. (2024) reported Phase 2 results for survodutide in MASH, demonstrating significant improvements in liver histology endpoints including steatohepatitis resolution and fibrosis improvement [2].

Dual Agonist Rationale

Pocai A (2014) reviewed the rationale for GLP-1/glucagon dual agonism, describing how the combination achieves complementary metabolic effects through hepatic and central mechanisms [3].